In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Bassel Abou-Khalil, MD, professor of neurology and director of the epilepsy division at Vanderbilt University, about the promising new antiepileptic drug (AED) ezogabine (Potiga), which was approved by the FDA in June 2011.
Dr. Abou-Khalil explains that ezogabine, whose generic name is retigabine outside the United States, has a unique mechanism of action for an AED in that it prolongs the opening of the potassium channel. He adds that in clinical trials, some of which he helped run, the drug was very effective at reducing seizure frequency when added to other AEDs. In addition to dizziness, fatigue, and somnolence, which are generally common side effects of AEDs, Dr. Abou-Kahlil notes that urinary retention and discoloration of the urine have been associated with ezogabine.
To listen to the podcast, click here
and scroll down to the October 14, 2011, episode.